• Clovis Oncology Inc., of Boulder, Colo. received notification from an independent data monitoring committee that approximately 65 percent of patients in its LEAP pivotal trial of CP-4126 for metastatic pancreatic cancer have been classified as hENT1-low. Clovis licensed CP-4126 from Clavis Pharma ASA, of Oslo, Norway in 2009.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter